Of all the biomarkers tested (Figure 3), p‐tau 217 exhibited diagnostic superiority for differentiating CAA from AD, with an AUC of 0.809 (95% CI, 0.707–0.912); p‐tau 217 significantly outperformed Aβ40, Aβ42, the Aβ42/40 ratio, and total tau (all p < 0.05). Here, MAPT is linked to Alzheimer disease.